Core Viewpoint - Apollo Technology Capital Corporation, a significant shareholder of MediPharm Labs Corp., has presented a plan aimed at revitalizing the company and enhancing shareholder value [1][6]. Shareholder Engagement - Shareholders are encouraged to vote for Apollo Capital's six director nominees using the "Gold Card" and to disregard MediPharm's "Green Card" [2][3]. - The communication emphasizes the urgency for shareholders to act in order to protect their investments [2][3]. Ownership and Influence - Apollo Capital, through its subsidiary Nobul Technologies Inc., owns approximately 3% of MediPharm's common shares, totaling 12,491,500 shares [4][6]. - The company is actively seeking to influence the board of directors through its proxy solicitation efforts [11]. Action Plan - Apollo Capital has outlined a commitment to execute an aggressive action plan aimed at increasing MediPharm's share price by over 10 times and preventing insolvency [6]. - The plan includes measures to address excessive executive compensation and rectify three years of value-destructive actions [6]. Legal and Regulatory Compliance - Apollo Capital has filed an amended dissident information circular in compliance with Canadian corporate and securities laws, detailing their director nominees and the rationale behind their actions [5][7]. - Shareholders are advised to read the amended circular carefully as it contains crucial information regarding the upcoming annual meeting [8].

Core Viewpoint - Apollo Capital and Pat McCutcheon emphasize the urgent need for change at MediPharm Lab Corp, advocating for a complete turnover at the board level to restore value for shareholders after years of mismanagement and declining share prices [1][2][5]. Group 1: Management and Governance Issues - MediPharm's share price has significantly collapsed over the past three years, while senior management has received over $10 million in compensation, raising concerns about governance and accountability [2][4]. - The current management has deviated from MediPharm's founding vision by entering the recreational cannabis market and engaging in dilutive mergers and acquisitions, which has not aligned with shareholder interests [2][3]. Group 2: Proposed Changes and Support - Apollo Capital proposes a new board of directors with relevant experience in medical cannabis and turnaround strategies, led by Regan McGee, to drive the company's stock price higher [3][4]. - Shareholders are urged to support Apollo's director nominees by voting the GOLD CARD in the upcoming AGM, as this aligns with the goal of enhancing shareholder value [4][8]. Group 3: Shareholder Engagement - Apollo Capital's business model focuses on investing in poorly managed companies and working with shareholders to secure votes for new governance that prioritizes share value growth [4][5]. - The strategic five-pillar plan for MediPharm has been made available to shareholders, outlining the steps needed to transform the company into a leading player in the medical cannabis sector [7].

Company Overview - Couchbase provides a cloud database platform designed for modern applications, including Couchbase Capella, Couchbase Server, and Couchbase Mobile, focusing on high performance and scalability for mission-critical applications [1] - Couchbase Capella is a fully managed database-as-a-service, while Couchbase Server is a multi-service NoSQL database with SQL-compatible query language SQL++ [1] - Couchbase Mobile is an embedded NoSQL database for mobile and edge devices, ensuring high data availability [1] Market Position - Couchbase operates in the document database space, alongside MongoDB, with few direct competitors, establishing a solid business model used in various applications [4] - Since its IPO on February 22, 2021, Couchbase's shares have declined over 20%, indicating challenges in the public market [4] Financial Performance - Revenue has increased annually by an average of 19.39% since the IPO, with gross margins consistently between 87% and 89% [5] - Selling, general, and administrative (SG&A) expenses were 91.94% of revenue in 2024, slightly above the average of 91.25% since the IPO, compared to MongoDB's 54.34% [5] - Couchbase has overhired sales personnel, leading to lower attainment rates of 40% to 50% compared to peers achieving 70% to 80% [5] Activist Involvement - Irenic Capital has taken a significant stake in Couchbase, making it one of its five largest positions, focusing on operational restructuring or a potential sale of the company [6][7] - The activist's approach may involve optimizing management and salesforce, improving operating margins while maintaining organic growth [6] Potential Outcomes - A sale to a larger strategic or financial acquirer could allow Couchbase to restructure costs and pursue margin-friendly growth away from public market pressures [7] - Haveli Investments, the largest shareholder with approximately 9.8% ownership, may seek to take Couchbase private, viewing it as undervalued [8] - Comparable transactions in the tech space suggest Couchbase could be valued around 5.2 times revenue, potentially offering a 20% premium to shareholders [8]